ArticlePloS one2022

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

Manish A Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.